Contineum Therapeutics Inc [CTNM] stock is trading at $4.74, up 7.00%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CTNM shares have gain 35.24% over the last week, with a monthly amount glided 15.61%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Contineum Therapeutics Inc [NASDAQ: CTNM] stock has seen the most recent analyst activity on October 22, 2024, when Robert W. Baird initiated its Outperform rating and assigned the stock a price target of $32. Previously, Stifel started tracking the stock with Buy rating on April 30, 2024, and set its price target to $29. On April 30, 2024, RBC Capital Mkts initiated with a Outperform rating and assigned a price target of $30 on the stock. Morgan Stanley started tracking the stock assigning a Overweight rating and suggested a price target of $25 on April 30, 2024.
Contineum Therapeutics Inc [CTNM] stock has fluctuated between $3.35 and $22.00 over the past year. Currently, Wall Street analysts expect the stock to reach $16 within the next 12 months. Contineum Therapeutics Inc [NASDAQ: CTNM] shares were valued at $4.74 at the most recent close of the market. An investor can expect a potential return of 237.55% based on the average CTNM price forecast.
Analyzing the CTNM fundamentals
Gross Profit Margin for this corporation currently stands at 0.25% with Operating Profit Margin at -244.11%, Pretax Profit Margin comes in at -205.91%, and Net Profit Margin reading is -205.91%. To continue investigating profitability, this company’s Return on Assets is posted at -0.25, Equity is -0.25 and Total Capital is -0.31. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.35 points at the first support level, and at 3.95 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.95, and for the 2nd resistance point, it is at 5.15.
Ratios To Look Out For
For context, Contineum Therapeutics Inc’s Current Ratio is 21.47. Also, the Quick Ratio is 21.47, while the Cash Ratio stands at 2.51.
Transactions by insiders
Recent insider trading involved Lorrain Daniel S., Chief Scientific Officer, that happened on Nov 25 ’24 when 1010.0 shares were sold. Chief Scientific Officer, Lorrain Daniel S. completed a deal on Nov 18 ’24 to sell 6190.0 shares. Meanwhile, Officer DANIEL LORRAIN bought 26370.0 shares on Nov 18 ’24.
